Health virtual twins for the personalised management of stroke related to atrial fibrillation

健康虚拟双胞胎用于房颤相关中风的个性化管理

• 批准号: 10102834
• 金额: $ 105.6万
• 依托单位: UNIVERSITY OF LIVERPOOL
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10102834
• 关键词: Health; virtual; twins; personalised; management

Atrial fibrillation (AF) is the most common heart arrhythmia worldwide, leading to life-limiting complications, high financial burden and significant resource utilisation. In Europe, stroke as a debilitating complication of AF, is amongst the commonest causes of death and the leading cause of disability. AF patients have a 5-fold increased risk for ischaemic stroke. Functional recovery from AF-related stroke (AFRS) is often unsatisfactory, leading to severe disability, reduced quality of life and high mortality. TARGET’s ambition is to develop novel personalised, integrated, multi-scale computational models (virtual twins) and decision-support tools for the AF-related stroke pathway, starting from the healthy state, pathophysiology and disease onset, progression, treatment and recovery. TARGET aims to help prevent AF and AFRS, optimise acute management and rehabilitation, reduce long-term disability, provide a better quality of life for patients and caregivers, and lower healthcare costs. We will ensure patients are at the heart of the project, and the association with experienced commercial partners will ensure the swift adoption of TARGET’s novel technologies. New observational data will be collected via 4 carefully designed prospective clinical studies, which will be used to test and validate the personalised tools and the virtual twin models using a clinical trial simulation (virtual/in-silico), to demonstrate evidence of clinically meaningful results. TARGET will also help consolidate existing mechanistic virtual twin models of the heart, the brain and the neuromusculoskeletal system, enriching these twins to deliver more complex tasks, and supporting research to move towards a more integrated human virtual twin. TARGET represents a milestone project to improve the care and rehabilitation of patients with AF and AFRS, introducing a paradigm shift in risk prediction, diagnosis and management of the disease, and accelerating translational research into practice.

心房颤动（AF）是全世界最常见的心律失常，导致生命并发症，高财务燃烧和大量资源利用。在欧洲，中风是AF的一种使人衰弱的并发症，是死亡的最常见原因之一，是残疾的主要原因。 AF患者患缺血性中风的风险增加了5倍。与AF相关的中风（AFRS）的功能恢复通常不令人满意，导致严重的残疾，生活质量降低和高死亡率。 Target的野心是开发新型的个性化，综合，多规模的计算模型（虚拟双胞胎）和与AF相关的中风途径的决策支持工具，从健康状态，病理生理学和疾病发作，进展，治疗，治疗和恢复开始。目标旨在帮助预防AF和AFR，优化急性管理和康复，减少长期残疾，为患者和看护人提供更好的生活质量，并降低医疗保健费用。我们将确保患者成为该项目的核心，并且与经验丰富的商业合作伙伴的联系将确保迅速采用Target的新技术。新的观察数据将通过4个精心设计的前瞻性临床研究收集，该研究将使用临床试验模拟（虚拟/silico）来测试和验证个性化工具和虚拟双胞胎模型，以证明临床上有意义的结果证据。目标还将有助于巩固心脏，大脑和神经肌肉骨骼系统的现有机械虚拟双胞胎模型，丰富这些双胞胎以提供更复杂的任务，并支持研究以迈向更整合的人类虚拟双胞胎。 Target代表了一个里程碑项目，旨在改善AF和AFRS患者的护理和康复，引入风险预测，诊断和管理疾病的范式转移，并将转化研究加速到实践中。